Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

David Wyles

Concepts (239)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Antiviral Agents
58
2025
712
11.420
 Why?
Hepatitis C, Chronic
31
2025
153
8.750
 Why?
Hepacivirus
46
2024
235
7.840
 Why?
Hepatitis C
27
2025
238
7.620
 Why?
Benzimidazoles
16
2020
162
4.370
 Why?
Drug Resistance, Viral
17
2018
110
3.270
 Why?
HIV Infections
28
2022
2720
3.130
 Why?
Coinfection
15
2020
131
3.120
 Why?
Ribavirin
15
2020
91
2.400
 Why?
Sofosbuvir
16
2022
58
2.330
 Why?
Quinoxalines
7
2019
65
2.320
 Why?
Sulfonamides
13
2020
496
2.300
 Why?
Fluorenes
7
2020
40
2.290
 Why?
Liver Cirrhosis
8
2020
280
2.230
 Why?
Viral Nonstructural Proteins
9
2018
58
2.000
 Why?
Drug Therapy, Combination
26
2020
1040
1.870
 Why?
Uridine Monophosphate
5
2016
15
1.730
 Why?
Carbamates
9
2020
46
1.500
 Why?
Anti-Retroviral Agents
5
2019
231
1.470
 Why?
Protease Inhibitors
10
2020
106
1.410
 Why?
Hepatitis B, Chronic
3
2019
18
1.380
 Why?
Proline
11
2020
76
1.290
 Why?
Pyrrolidines
9
2019
67
1.240
 Why?
Congresses as Topic
3
2021
215
1.210
 Why?
Hepatitis, Viral, Human
3
2021
25
1.180
 Why?
Genotype
19
2022
1839
1.020
 Why?
Cyclopropanes
11
2020
89
1.000
 Why?
Drug Users
2
2024
41
0.990
 Why?
Sustained Virologic Response
10
2020
37
0.940
 Why?
Lactams, Macrocyclic
10
2020
49
0.930
 Why?
Heterocyclic Compounds, 4 or More Rings
3
2017
19
0.820
 Why?
HIV-1
8
2020
836
0.810
 Why?
Virus Replication
7
2012
451
0.770
 Why?
Disease Eradication
1
2020
4
0.720
 Why?
Organophosphonates
4
2011
92
0.700
 Why?
Homosexuality, Male
2
2021
175
0.690
 Why?
Anti-HIV Agents
6
2020
754
0.670
 Why?
Humans
75
2025
129621
0.660
 Why?
Valine
7
2020
81
0.650
 Why?
Nucleic Acid Synthesis Inhibitors
2
2015
16
0.570
 Why?
Imidazoles
2
2015
234
0.550
 Why?
Ritonavir
6
2020
73
0.550
 Why?
Darunavir
1
2017
18
0.540
 Why?
Treatment Failure
5
2019
340
0.540
 Why?
Aminoisobutyric Acids
5
2019
7
0.530
 Why?
Uracil
5
2020
30
0.520
 Why?
Treatment Outcome
18
2023
10226
0.510
 Why?
Antiretroviral Therapy, Highly Active
3
2015
267
0.500
 Why?
Leucine
5
2019
108
0.500
 Why?
Anilides
5
2020
73
0.500
 Why?
Middle Aged
30
2025
31150
0.500
 Why?
Education, Medical, Continuing
1
2016
122
0.480
 Why?
Biomedical Research
1
2021
638
0.470
 Why?
Male
39
2025
63674
0.470
 Why?
Adenine
4
2020
256
0.460
 Why?
RNA, Viral
7
2015
619
0.450
 Why?
Oligopeptides
2
2013
257
0.450
 Why?
Viral Load
7
2020
448
0.440
 Why?
Pyridazines
1
2014
54
0.440
 Why?
2-Naphthylamine
5
2020
7
0.430
 Why?
Macrocyclic Compounds
3
2019
9
0.430
 Why?
Adult
29
2025
35572
0.420
 Why?
Female
37
2025
68770
0.420
 Why?
Purines
1
2014
172
0.410
 Why?
Quinolines
1
2014
156
0.410
 Why?
Replicon
3
2009
14
0.400
 Why?
Liver
1
2021
1839
0.400
 Why?
Disease Management
1
2016
589
0.390
 Why?
Scavenger Receptors, Class B
1
2012
11
0.390
 Why?
Aged
17
2024
22099
0.370
 Why?
Retreatment
2
2021
70
0.350
 Why?
Drug Synergism
3
2008
371
0.340
 Why?
Acquired Immunodeficiency Syndrome
2
2020
227
0.300
 Why?
Dideoxynucleosides
2
2005
20
0.300
 Why?
Liver Diseases
2
2016
290
0.300
 Why?
Interferon-alpha
4
2013
194
0.290
 Why?
Cytokines
1
2015
2017
0.280
 Why?
Amino Acid Substitution
2
2018
282
0.270
 Why?
Global Health
2
2020
329
0.270
 Why?
Cytosine
2
2009
46
0.260
 Why?
Hepatitis B virus
2
2019
35
0.240
 Why?
HIV
2
2019
226
0.230
 Why?
Mass Screening
3
2023
1149
0.230
 Why?
Hepatitis
1
2004
47
0.230
 Why?
Herpes Simplex
1
2005
93
0.230
 Why?
Alanine
2
2021
142
0.220
 Why?
Prevalence
3
2019
2564
0.210
 Why?
Interferons
2
2015
194
0.200
 Why?
Young Adult
10
2019
12426
0.200
 Why?
Mutation, Missense
3
2014
317
0.190
 Why?
Hospitals
2
2024
637
0.190
 Why?
Interferon beta-1a
1
2021
12
0.190
 Why?
Hepatitis A
1
2021
25
0.180
 Why?
Adenosine Monophosphate
1
2021
63
0.180
 Why?
Tenofovir
2
2020
231
0.180
 Why?
Hepatitis B
1
2021
63
0.180
 Why?
World Health Organization
1
2020
110
0.170
 Why?
Disease Progression
2
2019
2635
0.170
 Why?
Data Interpretation, Statistical
2
2018
335
0.160
 Why?
Polyethylene Glycols
2
2015
601
0.160
 Why?
United States
10
2025
13900
0.160
 Why?
Ribosomes
2
2010
164
0.150
 Why?
Esters
2
2009
74
0.150
 Why?
CD4 Lymphocyte Count
2
2017
266
0.150
 Why?
Immunologic Factors
1
2020
231
0.150
 Why?
Nucleic Acid Conformation
4
2014
706
0.140
 Why?
Hospitalization
2
2024
2070
0.140
 Why?
Alanine Transaminase
1
2018
153
0.140
 Why?
DNA, Viral
1
2019
350
0.140
 Why?
Genes, Viral
1
2016
82
0.130
 Why?
DNA Mutational Analysis
1
2018
387
0.130
 Why?
Mutation
2
2018
3717
0.130
 Why?
High-Throughput Nucleotide Sequencing
2
2016
487
0.130
 Why?
Molecular Structure
2
2008
482
0.130
 Why?
Patient Compliance
1
2020
565
0.130
 Why?
Survival Analysis
1
2019
1274
0.130
 Why?
Adolescent
5
2022
20391
0.120
 Why?
Dose-Response Relationship, Drug
2
2017
2012
0.120
 Why?
Regulatory Sequences, Ribonucleic Acid
1
2014
19
0.120
 Why?
Opiate Substitution Treatment
1
2016
136
0.120
 Why?
AIDS-Related Opportunistic Infections
1
2015
123
0.110
 Why?
Chemokines
1
2015
226
0.110
 Why?
Chemokine CXCL10
1
2014
34
0.110
 Why?
Drug Interactions
1
2015
394
0.110
 Why?
Phenylenediamines
1
2013
9
0.110
 Why?
Viral Proteins
2
2014
328
0.110
 Why?
Fibrosis
1
2016
520
0.110
 Why?
Prognosis
2
2019
3794
0.110
 Why?
Quality of Life
1
2025
2704
0.100
 Why?
Drug Combinations
3
2019
330
0.100
 Why?
Microbial Sensitivity Tests
2
2012
352
0.100
 Why?
Drug Discovery
1
2013
131
0.100
 Why?
Administration, Oral
1
2014
786
0.090
 Why?
Mental Disorders
1
2020
1030
0.090
 Why?
Cohort Studies
5
2024
5420
0.090
 Why?
Case-Control Studies
2
2017
3381
0.090
 Why?
Telemedicine
1
2020
788
0.090
 Why?
Models, Molecular
3
2012
1492
0.090
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2013
253
0.090
 Why?
Prodrugs
1
2011
48
0.090
 Why?
Nucleosides
1
2010
27
0.090
 Why?
Japan
2
2021
98
0.090
 Why?
Riboswitch
1
2012
67
0.090
 Why?
Prospective Studies
4
2023
7131
0.080
 Why?
Drug Administration Schedule
3
2017
769
0.080
 Why?
Cell Line, Tumor
2
2008
3215
0.080
 Why?
Risk Assessment
1
2019
3240
0.080
 Why?
Drug Design
1
2010
156
0.080
 Why?
Biomarkers
1
2020
3973
0.080
 Why?
Cell Line
2
2012
2781
0.080
 Why?
Piperidines
1
2010
198
0.080
 Why?
Body Mass Index
1
2017
2273
0.070
 Why?
Practice Guidelines as Topic
1
2016
1501
0.070
 Why?
Phenylthiourea
1
2008
5
0.070
 Why?
Immunity, Innate
1
2014
804
0.070
 Why?
Plasmids
1
2009
358
0.070
 Why?
Structure-Activity Relationship
1
2009
548
0.070
 Why?
Inhibitory Concentration 50
1
2006
86
0.070
 Why?
Luciferases
1
2006
148
0.070
 Why?
Genes, Reporter
1
2006
267
0.060
 Why?
Thailand
1
2025
15
0.060
 Why?
Pandemics
2
2024
1485
0.060
 Why?
Saquinavir
1
2004
1
0.060
 Why?
Simplexvirus
1
2005
80
0.060
 Why?
Indinavir
1
2004
7
0.060
 Why?
Uganda
1
2025
72
0.060
 Why?
Nelfinavir
1
2004
9
0.060
 Why?
Drug Labeling
1
2005
41
0.060
 Why?
Nevirapine
1
2004
17
0.060
 Why?
Oxazines
1
2004
28
0.060
 Why?
Benzoxazines
1
2004
30
0.060
 Why?
Lopinavir
1
2004
30
0.060
 Why?
Brazil
1
2025
154
0.060
 Why?
Time Factors
1
2015
6556
0.060
 Why?
Alkynes
1
2004
55
0.060
 Why?
Zidovudine
1
2004
78
0.060
 Why?
Liver Function Tests
1
2004
112
0.060
 Why?
Pregnancy
1
2017
6402
0.060
 Why?
South Africa
1
2025
192
0.060
 Why?
Reverse Transcriptase Inhibitors
1
2004
83
0.060
 Why?
Transfection
1
2006
911
0.060
 Why?
Carcinoma, Hepatocellular
1
2006
272
0.060
 Why?
Bone Marrow Transplantation
1
2005
274
0.060
 Why?
Pyrimidinones
1
2004
103
0.060
 Why?
Recombinant Fusion Proteins
1
2006
643
0.050
 Why?
Double-Blind Method
2
2021
1876
0.050
 Why?
Polyphosphates
1
2022
37
0.050
 Why?
Republic of Korea
1
2021
28
0.050
 Why?
Singapore
1
2021
20
0.050
 Why?
Liver Neoplasms
1
2006
640
0.050
 Why?
Dried Blood Spot Testing
1
2022
94
0.050
 Why?
Retrospective Studies
5
2019
14519
0.050
 Why?
Emergency Service, Hospital
2
2023
1902
0.050
 Why?
Mexico
1
2021
190
0.050
 Why?
Protein Biosynthesis
2
2014
406
0.040
 Why?
Raltegravir Potassium
1
2019
17
0.040
 Why?
Intensive Care Units
1
2024
738
0.040
 Why?
Clinical Trials, Phase II as Topic
1
2019
72
0.040
 Why?
Clinical Trials, Phase III as Topic
1
2019
93
0.040
 Why?
Drug Resistance, Multiple, Viral
1
2017
11
0.030
 Why?
Longitudinal Studies
1
2024
2716
0.030
 Why?
Kinetics
1
2020
1642
0.030
 Why?
Oxygen
1
2021
915
0.030
 Why?
Medicaid
1
2020
433
0.030
 Why?
Program Evaluation
1
2020
875
0.030
 Why?
Incidence
2
2013
2644
0.030
 Why?
RNA
1
2022
883
0.030
 Why?
Cell-Free System
1
2014
48
0.030
 Why?
Hepatitis C Antibodies
1
2014
9
0.030
 Why?
Spain
1
2014
34
0.030
 Why?
Enzyme-Linked Immunosorbent Assay
1
2016
833
0.030
 Why?
Polymorphism, Genetic
1
2017
640
0.030
 Why?
Patient Acceptance of Health Care
1
2020
759
0.030
 Why?
Aged, 80 and over
2
2019
7084
0.030
 Why?
Patient Reported Outcome Measures
1
2017
372
0.030
 Why?
Risk Factors
2
2020
9763
0.030
 Why?
Patient Care
1
2014
109
0.030
 Why?
Withholding Treatment
1
2013
71
0.030
 Why?
Early Diagnosis
1
2014
234
0.030
 Why?
Plasma
1
2014
206
0.020
 Why?
Fluorescence Resonance Energy Transfer
1
2012
177
0.020
 Why?
Virus Internalization
1
2010
47
0.020
 Why?
Ligands
1
2012
622
0.020
 Why?
Recombinant Proteins
1
2013
1304
0.020
 Why?
Pilot Projects
1
2015
1587
0.020
 Why?
Magnesium
1
2009
153
0.020
 Why?
Lamivudine
1
2009
61
0.020
 Why?
Genome, Viral
1
2009
129
0.020
 Why?
Referral and Consultation
1
2014
733
0.020
 Why?
Logistic Models
1
2013
1988
0.020
 Why?
Phenotype
1
2014
3076
0.020
 Why?
Base Sequence
1
2009
2142
0.020
 Why?
Severity of Illness Index
1
2013
2742
0.020
 Why?
Randomized Controlled Trials as Topic
1
2011
1367
0.010
 Why?
Mice, Transgenic
1
2009
2119
0.010
 Why?
Animals
2
2018
35360
0.010
 Why?
Substance-Related Disorders
1
2011
1022
0.010
 Why?
Signal Transduction
1
2009
4925
0.010
 Why?
Mice
1
2009
16937
0.010
 Why?
Wyles's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (239) concept(s)
_
Co-Authors Expand Description
See all (18) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)